ACO Working Group


  • Jerry Krishnan – Lead
  • Caroline Gouder
  • Chantal Raherison-Semjen
  • Claus Vogelmeier
  • David Price
  • Dermot Ryan
  • Dirkje Postma
  • Emilio Pizzichini
  • Eric van Ganse
  • George Christoff
  • Glenn Crater
  • Guy Brusselle
  • Janwillem Kocks
  • Jean Bourbeau
  • Leif Bjermer
  • Marc Miravitlles
  • Miguel Roman Rodriguez
  • Nicolas Roche
  • Pascal Chanez
  • Renaud Louis
  • Ronald Dandurand
  • Victoria Carter


The latest meeting of the ACOS Working Group took place in London during the ERS 2016 at the RCGP.

Work Plan

Only formally recognised by GINA/GOLD for the first time in 2014, ACOS is an area of growing research interest and one particularly “ripe” for real-life research given the typical exclusion of asthma patients form COPD RCTs and vice versa. Although the 2014 GINA/GOLD joint ACOS statement is a first step towards recognising and defining the syndrome, the ACOS Working Group felt the GOLD/GINA definition is limited because it lacks specificity and does not differentiate between the types of ACOS clinicians see in routine clinical practice. The REG ACOS Working Group is still relatively new and initial activities are focussing on

  • Identifying database resources for ACOS research;
  • Identifying the key initial research questions and reviewing possible study designs to answer them.

There are a number of studies the working group is interested in pursuing with a view to:

  • Better characterising ACOS as an entity;
  • Evaluating ICS treatment response in ACOS (and opportunities for ICS dose reduction in non responders);
  • The role of eNO as a biomarker for ACOS, predictor of ICS treatment response and guide for ICS withdrawal, as well as its potential role to guide optimum treatment of exacerbations (e.g. oral steroids vs antibiotics).


Working Group Documents